인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
Latent cytomegalovirus (CMV) can reactivate in times of immunosuppression or during critical illness and is associated with worse prognosis, but the benefit of using antiviral medications in otherwise immunocompetent individuals during CMV reactivation is unclear. This study aims to systematically review the effect of using antiviral medications on clinical outcomes in immunocompetent population. Database searches were performed in EMBASE, Medline, Scopus, CINAHL Complete, as well as in two trial registries ClinicalTrials.gov and ICTRP Search Portal. Search terms focused on CMV and antiviral medications among non-immunocompromised hosts admitted to the hospital. Effect estimates were combined using a Random Effects meta-analysis. Four randomized controlled trials and two cohort studies were included (total N = 785). There was no significant difference in the use of antiviral medications on composite measure of mortality (p = 0.18) either when given as preemptive treatment or as prophylaxis (p = 0.42), or when subgrouped by randomized studies versus observational studies were compared (p = 0.86). There was no difference in overall intensive care unit length of stay (p = 0.40) or duration of hospitalization (p = 0.25). Using antiviral medications in immunocompetent individuals with CMV reactivation did not affect mortality, ICU duration, or hospital duration. No conclusion can be reached regarding decrease in respiratory support post antiviral use. This study is not a clinical trial.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
